drugset / Trial / NCT03093389
Tolerability and Steady-state Pharmacokinetics of BIA 6-512
RandomizedSequentialDouble-blindTreatment
Summary
To investigate the tolerability and safety of four multiple-dose regimens of BIA 6-512 (25 mg, 50 mg, 100 mg, and 150 mg 6 times daily) in healthy volunteers and to characterise the steady-state pharmacokinetic profiles of BIA 6-512 (25 mg, 50 mg, 100 mg, and 150 mg 6 times daily) in healthy volunteers.
Timeline
- Start
- 2005-05-11
- Primary completion
- 2005-07-29
- Completion
- 2005-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resveratrol | Small molecule | 25 mg | Oral |
| Subject | Resveratrol | Small molecule | 50 mg | Oral |
| Subject | Resveratrol | Small molecule | 100 mg | Oral |
| Subject | Resveratrol | Small molecule | 150 mg | Oral |